<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368547</url>
  </required_header>
  <id_info>
    <org_study_id>16-001684</org_study_id>
    <secondary_id>NCI-2016-01768</secondary_id>
    <secondary_id>16-001684</secondary_id>
    <secondary_id>P30CA016042</secondary_id>
    <nct_id>NCT03368547</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery</brief_title>
  <official_title>68Ga-PSMA-11 PET/CT for Staging of Intermediate and High Risk Prostate Cancer Prior to Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed
      tomography (CT) works in imaging patients with intermediate or high risk prostate cancer
      before surgery. Diagnostic procedures, such as PET/CT scans, may help find and diagnose
      prostate cancer and find out how far the disease has spread.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11)
      PET/CT for the detection of regional nodal metastases compared to pathology at radical
      prostatectomy on a per patient basis.

      OUTLINE:

      Patients receive 68Ga-PSMA-11 intravenously (IV) and undergo a single PET/CT scan over 45-60
      minutes at week 1.

      After completion of study, patients are followed up at 1-3 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative predictive value of 68Ga-PSMA-11 positron emission tomography for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis and using nodal regional correlation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive predictive value of 68Ga-PSMA-11 positron emission tomography for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis and using nodal regional correlation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity of 68Ga-PSMA-11 positron emission tomography for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis and using nodal regional correlation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of 68Ga-PSMA-11 positron emission tomography for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis and using nodal regional correlation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of 68Ga-PSMA-11 positron emission tomography for the detection of extra-pelvic nodal metastases, visceral metastases, and osseous metastases compared to biopsy and imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of 68Ga-PSMA-11 positron emission tomography for the detection of extra-pelvic nodal metastases, visceral metastases, and osseous metastases compared to biopsy and imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of 68Ga-PSMA-11 positron emission tomography for the detection of extra-pelvic nodal metastases, visceral metastases, and osseous metastases compared to biopsy and imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of 68Ga-PSMA-11 positron emission tomography for the detection of extra-pelvic nodal metastases, visceral metastases, and osseous metastases compared to biopsy and imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gross-tumor-volume using 68Ga-PSMA-11 positron emission tomography and multiparametric magnetic resonance imaging</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be compared to tumor extent in histopathology.</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of 68Ga-PSMA-11 positron emission tomography on clinical management</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 3 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of osseous and distant metastatic lesions</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Inter-reader agreement of 68Ga-PSMA-11 PET/CT</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Cohen's kappa coefficient, Fleiss' kappa coefficient</description>
  </other_outcome>
  <other_outcome>
    <measure>Lesional standardized uptake value maximum from 68Ga-PSMA-11</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be correlated with immunohistochemical stainings (e.g. PSMA, PI3K, Akt) and Gleason score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Negative predictive value for detection of regional nodal metastases in comparison to cross sectional imaging performed contemporaneously with the 68Ga-PSMA-11 positron emission tomography</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Positive predictive value for detection of regional nodal metastases in comparison to cross sectional imaging performed contemporaneously with the 68Ga-PSMA-11 positron emission tomography</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </other_outcome>
  <other_outcome>
    <measure>PSA progression free survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will compare patients with and without pelvic nodal metastases.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sensitivity and specificity on lesions level for 68Ga-PSMA-11 positron emission tomography and multiparametric magnetic resonance imaging</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sensitivity for detection of regional nodal metastases in comparison to cross sectional imaging performed contemporaneously with the 68Ga-PSMA-11 positron emission tomography</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Specificity for detection of regional nodal metastases in comparison to cross sectional imaging performed contemporaneously with the 68Ga-PSMA-11 positron emission tomography</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of radiotherapy gross-target-volume (GTV) using 68Ga-PSMA-11 PET and mpMRI to tumor extent in histopathology</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">271</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stage IIB Prostate Cancer AJCC v7</condition>
  <condition>Stage III Prostate Cancer AJCC v7</condition>
  <condition>Stage IV Prostate Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 68Ga-PSMA-11 IV and undergo a single PET/CT scan over 45-60 minutes at week 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, PET/CT)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>positron emission tomography scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven prostate adenocarcinoma

          -  Planned prostatectomy with lymph node dissection

          -  Intermediate to high-risk disease (as determined by elevated prostate specific antigen
             [PSA] [PSA &gt; 10], tumor [T]-stage [T2b or greater], Gleason score [Gleason score &gt; 6]
             or other risk factors)

          -  Able to provide written consent

          -  Karnofsky performance status of &gt;= 50 (or Eastern Cooperative Oncology Group
             [ECOG]/World Health Organization [WHO] equivalent)

          -  Diagnostic CT or magnetic resonance imaging (MRI) as part of the PET study or
             performed within one month of PSMA PET

        Exclusion Criteria:

          -  Patients not capable of getting PET study due to weight, claustrophobia, or inability
             to lay still for the duration of the exam

          -  Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy including focal
             ablation techniques (high-intensity focused ultrasound ablation [HiFu])
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Czernin</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Czernin</last_name>
      <phone>310-206-3226</phone>
    </contact>
    <investigator>
      <last_name>Johannes Czernin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

